It is universally agreed that a clinical trial provides invaluable insights and knowledge, particularly when done well, through the use of randomization, blinded allocation, by including a control arm, and by focusing on a clinical outcome as opposed to a surrogate marker of disease. Clinical trials form the basis of many of the most important determinations in medicine and health care broadly, including the US Food and Drug Administration’s (FDA’s) determination of medical product safety and efficacy, the determination made by the Centers for Medicare & Medicaid Services and other commercial payers to provide coverage for a medical product, and clinical recommendations made by professional societies and government agencies to guide practice. But a common objection to performing a clinical trial is that trials are expensive, requiring extensive time and resources (although such costs pale in comparison to the costs of the health care interventions spent after approval, with or without coverage).
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ross JS. Clinical Trials—We Get What We Pay For. JAMA Intern Med. 2018;178(11):1457. doi:10.1001/jamainternmed.2018.3930
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: